Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

  Email address:
   

How Does the Merck/Schering-Plough Merger Affect China?

publication date: Mar 11, 2009

Merck has offered $41.1 billion to acquire fellow big pharma Schering-Plough, an acquisition that, if completed, is expected to close in Q4 of 2009. From a China perspective, the two companies seem very similar: both market their pharmaceutical products in China, but neither one has established a major R&D presence there, nor have they been especially active in China business development projects. Will that change after the merger?  More details...

Stock Symbols: (NYSE: MRK) (NYSE: SGP)



Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes

Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China

Partner Event
November 2-3, 2023 | Shanghai
November 7-8, 2023 | Digital